Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 18, 2004
Companies intend to continue a pre-existing collaboration in the development of less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation.
-
Feb 17, 2004
Analyst meeting on Monday, February 23 will focus on the Company's outlook for 2004 and beyond.
-
Feb 17, 2004
New 120,000 square-foot building at the Maple Grove campus will house primarily research and development laboratories and offices.
-
Feb 9, 2004
Site will initially serve as the new headquarters for the Company's growing Endosurgery group.
-
Feb 6, 2004
FDA team indicated it intends to recommend approval to manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system for the U.S. market.
-
Feb 4, 2004
ARRIVE registry will collect and analyze "real-world" safety and clinical outcomes data for the TAXUS™ Express2™ paclitaxel-eluting stent system.
-
Jan 30, 2004
United States District Court for the District of Delaware has scheduled a trial for June 2005.
-
Jan 29, 2004
Approval will enable patients to be treated with the TAXUS stent system in private clinics and hospitals; product was previously available in France primarily through public hospitals.
-
Jan 28, 2004
A live webcast and replay of the February 3 session will be available. Learn how to tune in.
-
Jan 22, 2004
A replay of the February 2 conference call will also be available. Learn how to tune in.